Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 3/20 | 0.30 |
| ▸ | CTSK | P43235 | 3/20 | 0.30 |
| ▸ | CTSS | P25774 | 2/20 | 0.30 |
| ▸ | CTSC | P53634 | 2/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15105646 | 1.00 | BTK (0.36) | BTKUSP30UCHL1HDAC1HDAC8 | |
| SCHEMBL796403 | 0.94 | BTK (0.35) | BTKUSP30UCHL1 | |
| SCHEMBL789168 | 0.87 | CYP3A4 (0.36) | USP30UCHL1HDAC1HDAC8HDAC6 | |
| SCHEMBL790109 | 0.87 | CYP3A4 (0.36) | USP30UCHL1HDAC1HDAC8HDAC6 | |
| SCHEMBL789298 | 0.84 | FPR2 (0.40) | HDAC1HDAC8HDAC6ROCK2ROCK1 | |
| SCHEMBL15022686 | 0.84 | FPR2 (0.40) | HDAC1HDAC8HDAC6ROCK2ROCK1 | |
| SCHEMBL789423 | 0.81 | HDAC1 (0.35) | HDAC1HDAC8HDAC6ROCK2ROCK1 | |
| SCHEMBL789424 | 0.80 | GPR119 (0.32) | HDAC1HDAC8HDAC6 | |
| SCHEMBL797270 | 0.77 | FPR2 (0.35) | BTK | |
| SCHEMBL16011132 | 0.77 | GPR119 (0.35) | BTKHDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616074-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | Array Biopharma, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130184257-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-07-18 | — | — | US | disclosed |
| WO-2012037393-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184257-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR180 | BTK 3212/4885USP30 2304/4885UCHL1 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.